Anne Clem Whitaker
Known title: DirectorCIK: 0001593283
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Lisata reports first patient dose in MAR002 acromegaly trial. Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.
Transaction History
| ICLR | ▼ Sell | Open Market | 88 | $14K | 8/11/2026 | View on chart |
| ICLR | ▼ Sell | Open Market | 96 | $16K | 8/11/2026 | View on chart |
| ICLR | ▼ Sell | Open Market | 590 | $97K | 8/11/2026 | View on chart |
| ICLR | ▼ Sell | Open Market | 67 | $11K | 8/11/2026 | View on chart |
| ICLR | ▲ Buy | Option Exercise | 1,732 | — | 8/10/2026 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 2,323 | $12K | 5/16/2023 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 4,400 | $25K | 5/15/2023 | View on chart |
| OSUR | ▲ Buy | Grant | 20,000 | $105K | 5/16/2022 | View on chart |
| LSTA | ▲ Buy | Grant | 65,430 | $0 | 1/10/2022 | View on chart |
| OSUR | ▲ Buy | Grant | 10,563 | $105K | 11/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Icon plc (ICLR) gets new US trial boost and UBS price target update
Icon plc is highlighted by a U.S. Health and Human Services project aimed at speeding up clinical trials, which could improve the pace of its drug development. UBS has lifted its rating to neutral and set a $195 target, reflecting confidence in the company’s prospects. The stock sits near a key support level and shows a mild RSI, indicating moderate purchase pressure. These developments suggest increased attention from analysts and potential for short‑term volatility.
Icon plc (ICLR) gets new US trial boost and UBS price target update. Icon plc is highlighted by a U.S. Health and Human Services project aimed at speeding up clinical trials, which could improve the pace of its drug development. UBS has lifted its rating to neutral and set a $195 target, reflecting confidence in the company’s prospects. The stock sits near a key support level and shows a mild RSI, indicating moderate purchase pressure. These developments suggest increased attention from analysts and potential for short‑term volatility.